J
Jouni Tuisku
Researcher at University of Turku
Publications - 46
Citations - 935
Jouni Tuisku is an academic researcher from University of Turku. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 35 publications receiving 543 citations. Previous affiliations of Jouni Tuisku include University of Manchester & University Hospital of Basel.
Papers
More filters
Journal ArticleDOI
In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195
Eero Rissanen,Jouni Tuisku,Johanna Rokka,Teemu Paavilainen,Riitta Parkkola,Juha O. Rinne,Laura Airas +6 more
TL;DR: The finding of increased 11C-PK11195 binding in the NAWM of SPMS patients is in line with the neuropathologic demonstration that activated microglial cells are the source of diffuse NAWM inflammation.
Journal ArticleDOI
Adenosine A2A Receptors in Secondary Progressive Multiple Sclerosis: A [11C]TMSX Brain PET Study:
Eero Rissanen,Jere Virta,Teemu Paavilainen,Jouni Tuisku,Semi Helin,Pauliina Luoto,Riitta Parkkola,Juha O. Rinne,Laura Airas +8 more
TL;DR: It is shown that A2ARs are increased in the brain of SPMS patients, and that [ 11 C]TMSX-PET provides a novel approach to learn about central nervous system pathology in SPMS in vivo.
Journal ArticleDOI
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Marcus Sucksdorff,Markus Matilainen,Jouni Tuisku,Eero Polvinen,Anna Vuorimaa,Johanna Rokka,Marjo Nylund,Eero Rissanen,Laura Airas +8 more
TL;DR: Increased microglial and macrophage activation, as revealed by brain TSPO-PET, predicts multiple sclerosis progression independent of relapses during 4-year follow-up, and may contribute to diffuse neural damage leading to multiple sclerosis progress.
Journal ArticleDOI
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.
Jouni Tuisku,Jouni Tuisku,Pontus Plavén-Sigray,Edward C. Gaiser,Laura Airas,Laura Airas,Haidar Al-Abdulrasul,Haidar Al-Abdulrasul,Anna Brück,Anna Brück,Richard E. Carson,Ming-Kai Chen,Kelly P. Cosgrove,Laura L. Ekblad,Irina Esterlis,Lars Farde,Anton Forsberg,Christer Halldin,Semi Helin,Eva Kosek,Mats Lekander,Mats Lekander,Noora Lindgren,Päivi Marjamäki,Eero Rissanen,Eero Rissanen,Marcus Sucksdorff,Marcus Sucksdorff,Andrea Varrone,Andrea Varrone,K. Collste,Jean-Dominique Gallezot,Ansel T. Hillmer,Yiyun Huang,Caroline Olgart Höglund,Jarkko Johansson,Aurelija Jucaite,Jon Lampa,Nabeel Nabulsi,Brian Pittman,Christine M. Sandiego,Per Stenkrona,Juha O. Rinne,Juha O. Rinne,David Matuskey,Simon Cervenka +45 more
TL;DR: Findings provide evidence that individual biological properties may contribute significantly to the high variation shown in TSPO binding estimates, and suggest that age, BMI and sex can be confounding factors in clinical studies.
Journal ArticleDOI
Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
Marcus Sucksdorff,Eero Rissanen,Eero Rissanen,Jouni Tuisku,Salla Nuutinen,Teemu Paavilainen,Johanna Rokka,Juha O. Rinne,Juha O. Rinne,Laura Airas,Laura Airas +10 more
TL;DR: Fingolimod treatment reduced microglial/macrophage activation at the site of focal inflammatory lesions, presumably by preventing leukocyte trafficking from the periphery, and opens new vistas for designing future therapeutic studies in MS that use the evaluation of microglia activation as an imaging outcome measure.